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Tiivistelmä  
Yhden nukleotidin variantti-genotyypitys  (SNV-genotyypitys) on menetelmä, jota voisi 
soveltaa rutiininomaisesti syöpä-diagnostiikassa. Sitä ei käytetä, koska teknologiat joita 
menetelmä hyödyntää ovat suhteellisen uusia. Genotyypitys-laitteiden tulee olla luotettavia ja 
tarkkoja, koska syöpä-DNA:n määrä kudosnäytteissä voi olla hyvin vähäinen.  Formaliinilla 
kiinnitetyt ja parafiiniin valetut näytteet (FFPE-näytteet) ovat esimerkki kudosnäytteistä, 
joissa on pieni määrä DNA:ta. Toisen sukupolven sekvensointia (NGS) ja reaali-aikaista 
kvantitatiivista PCR:ä (qPCR) voisi mahdollisesti käyttää SNV-genotyypityksessä, kun 
kudosnäytteissä on pieniä määriä DNA:ta. Tässä tutkimuksessa genotyypitettiin näytteitä, 
joissa oli eri osuuksia syöpä-DNA:ta kahdella eri menetelmällä: NGS:lla Illuminan MiSeqillä 
ja qPCR:lla Fluidigmin BioMark HD:llä. Tulokset osoittavat, että MiSeq kykenee 
systemaattisesti havaitsemaan yhden nukleotidin variantteja näytteistä, joissa on 10 % syöpä-
DNA:ta, joka tarkoittaa 22,5 ng DNA:ta. BioMark HD kykenee havaitsemaan yhden 
nukleotidin variantteja näytteistä, joissa on 20 % syöpä-DNA:ta, joka tarkoittaa 12,0 ng 
DNA:ta. Näiden tulosten lisäksi, BioMark HD on luotettavampi, koska se havaitsi kahdeksan 
kymmenestä variantista, kun MiSeq havaitsi vain neljä. 
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Abstract 
Single nucleotide variant genotyping (SNV genotyping) is a method which could be used 
routinely for cancer diagnostics. It is not, because the technologies utilized are relatively new. 
Genotyping instruments need to be reliable and precise because the amounts of cancer DNA 
found in tissue samples can be very small. Formalin fixed paraffin embedded samples (FFPE 
samples) are an example of tissue samples that contain small amounts of DNA. SNV 
genotyping with next-generation sequencing (NGS) and quantitative real-time PCR (qPCR) 
could possibly be used for tissue samples containing small amounts of DNA. In this study 
samples with different fractions of cancer DNA were genotyped by two different methods: 
NGS with Illumina’s MiSeq and qPCR with Fluidigm’s BioMark HD. The results show that 
MiSeq is able to systematically detect single nucleotide variants from samples with a 10% 
fraction of DNA, representing 22.5 ng of DNA. BioMark HD is able to detect single 
nucleotide variants from 20% DNA fractions, representing 12.0 ng of DNA. In addition to 
these results, BioMark HD is more reliable, because it detected eight out of ten variants, while 
MiSeq only detected four.  
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1. Introduction 
Nucleic acid-based diagnostic methods for finding biomarkers are being researched for 
possible clinical usage (1). Genomic alterations such as single nucleotide variants (SNVs), 
which may cause cancer and which are the most common genomic alterations found in cancer 
(2), need to be recognized in a simple manner. Tissue samples may have very low frequencies 
of genomic alterations (2), including variants such as single nucleotide polymorphisms 
(SNPs). This is partially because cancerous tissues also have non-cancerous cells in them. 
Some samples have small amounts of DNA in them to begin with. 
 
Hospitals and research groups around the world have thousands of formalin-fixed and paraffin 
embedded (FFPE) samples, which contain small amounts of DNA that could potentially be 
used for studies (3, 4). Biopsy samples are commonly stored as FFPE samples because they 
can be stored for very long periods of time. The average age of FFPE samples used in 
hospitals is 20 years (1). This means that FFPE samples can be used in retrospective studies 
(3, 4), which are convenient for patients, because there is no need of new tissue. The amount 
of usable DNA in FFPE samples is small due to several reasons. The samples themselves are 
usually quite small, which directly reflects on the amount of DNA, but also DNA is always 
lost from such samples due to the method of sample preparation. FFPE preparation methods 
compromise the quality of the DNA because DNA-tissue protein cross-links form (5, 6). It 
appears then, that very sensitive instruments are required for cancer detection and the study of 
FFPE samples. Measurements done with FFPE derived DNA were not performed in the scope 
of this study however. 
 
Instruments with different genotyping techniques are manufactured for finding genomic 
variants. There are different techniques for genotyping such as microarray techniques (7), 
sequencing (8), and polymerase chain reaction (PCR) (9), to name a few. However, some 
techniques are more suitable for some samples than others (8). Some instruments and methods 
require larger amounts of starting DNA, in which case they may not be suitable for 
genotyping small cancer tissue or FFPE samples. The instruments may not be able to detect 
genomic alterations present as minor allele fractions (MAFs).  
  
How small are the amounts of DNA that can be extracted from FFPE samples for subsequent 
study? Gilbert et al. 2007 did a study where they compared the published methods of DNA 
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recovery related to FFPE samples. Their results showed that DNA extraction yielded mean 
and median values of 169 ng/μl and 54 ng/μl respectively. If most samples yield 
approximately 54 ng/μl of DNA, is it enough for genotyping with next-generation sequencing 
(NGS) or quantitative real-time PCR (qPCR)? 
 
A study by Beltran et al. 2013 showed that NGS can be used on DNA from FFPE samples. 
According to them 55 ng of DNA was required in order to have deep sequence coverage. 
According to Swango et al. 2007, as little as 1 ng of DNA can be used for genotyping with 
qPCR (10). In short, both NGS and qPCR methods could be used for samples with small 
amounts of DNA. 
 
NGS could have a large impact on cancer diagnoses. This form of sequencing has proven to 
be very useful when studying cancer genomes (2), and is the most commonly used type of 
sequencing for FFPE samples nowadays (4). The small amounts of cancer genomes in 
samples is not a problem if NGS is used (2). qPCR provides another way to genotype. 
 
There are many genotyping methods involving PCR (11), but they do not give quantitative 
results (12). qPCR is able to give such results in real-time as the PCR reaction occurs (12). 
This makes qPCR a versatile tool. qPCR can be used as a tool for diagnosing cancer and it 
can be used to determine patients’ prognoses (12). 
 
Clinical use of sequencing (2) and qPCR technologies (12) could lead to early diagnoses of 
cancer, faster responses to treatment and better prognoses. Genotyping could also be used as a 
method to find biomarkers common to cancer and to ascertain whether dissemination has 
occurred (2). It could also be used for checking whether or not the cancer treatments used 
have diminished the cancers, if tissue samples were available after treatment. In the future, 
making therapeutic plans for cancer patients will be assisted by the use of genome-based 
methods (2). This however, is still in the future. To get to this future it is necessary to improve 
our understanding of the genotyping technology at our disposal at the moment. 
 
In this study samples with different fractions of cancer DNA were genotyped by two different 
methods. We wanted to find out if one of the methods were more sensitive to small fractions 
of cancer DNA containing SNVs. The first method was sequencing with Illumina’s MiSeq. 
Agilent’s HaloPlex Cancer Research Panel was used for making a DNA library and a target 
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enrichment protocol was used for capturing the sequences of interest. These sequences were 
then sequenced with MiSeq Benchtop Sequencer, which uses NGS technology. The sequencer 
uses Illumina’s own sequencing by synthesis technology for strand extension 
(http://www.illumina.com/documents/products/datasheets/datasheet_miseq.pdf, 16.06.2016), 
in combination with cyclic reversible termination, single molecule templates and real-time 
sequencing (8). 
 
The second genotyping method was qPCR. Fluidigm’s BioMark HD qPCR was used for SNV 
genotyping. The instrument uses integrated fluid circuits (IFCs) in its 96.96 well plates which 
allows for high throughput, samples consisting of nanoliter volumes and automation 
(https://www.fluidigm.com/ifcs, 27.06.2016). 
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2. Literature Review 
 
2.1 Prostate cancer 
Out of all of the cancer related deaths in the Western world, prostate cancer deaths are among 
the top of the list (13). Histological prostate cancer is a form of cancer in which the cancer 
may remain indolent (14). An estimation of 40% of men over 50 years of age have 
histological prostate cancer (14). Usually during the progression of prostate cancer, 
approximately 40% of those who have localized prostate cancer develop metastases (13). 
Castration resistant prostate cancer is the last phase of the spectrum of the disease (13). The 
progression of the cancer is accompanied with a myriad of genetic alterations. 
 
Genomic alterations can affect genes or regulatory pathways involved in tumorigenesis and 
disease progression (13). Different kinds of genomic alterations, such as structural alterations, 
indels and substitutions, play a role in prostate cancer development and progression (13). 
Some alterations can be found in genes present in the germline, such as MSR1 and RNASEL 
(HPC1) (14). The genes AR, PTEN and p53 among many others, are frequently mutated in 
somatic prostate cancer (14). Copy number variation can also be commonly found in genes 
KLF5 and MYC, to name a few (14). Depending on the type of prostate cancer, different 
therapies are available. 
  
Therapies vary from surgery to pathways-based therapies. Several forms of surgery are used 
for the removal of prostate cancer, such as open surgery and minimally invasive radical 
surgery (15). Surgery and other forms of therapy are often combined. As an example, radical 
prostatectomy and radiotherapy can be combined in the curative treatment of localized 
prostate cancer (15). Chemotherapy is also used (15). High intensity focused ultrasound 
therapy has also been used in some cases of prostate cancer, but the efficacy of the treatment 
is still questionable (15). Pathway-based therapies are also used to alter cell signaling through 
pathways affecting tumor suppressor genes and oncogenes (14). An example of such therapies 
is the use of a therapeutic agent called rapamycin that inhibits mTOR protein kinase, which is 
involved in controlling the cell cycle (14). In the case of castration resistant prostate cancer, 
there is no curative therapy (13). In such cases, and also in cases with metastases, androgen 
ablation therapy is used (15). There are vaccine based immunotherapies being developed, but 
they are not in clinical use yet (15). In cases where the cancer is low-risk, active surveillance 
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and watchful waiting are common approaches (15, 16). Regardless of the type of therapy 
chosen, early diagnosis is important.  
 
The sensitivity of prostate cancer detection has increased. This is due to the use of prostate-
specific antigens (PSA) in prostate cancer detection and in following the progression of the 
cancer (17). In combination with histological methods, the Gleason Score is used for 
diagnosing prostate cancer (14). Genomic biomarkers are of great interest, since their use in 
the clinics could aid making diagnoses and prognoses (13). Studying FFPE samples of old 
prostate cancer biopsies could bring more understanding to the field. 
 
2.2 Breast Cancer 
Breast cancer related deaths are among the most common cancer related deaths in the world 
(http://www.who.int/mediacentre/factsheets/fs297/en/, 18.08.2016). The most common types 
of breast cancer are ductal or invasive and lobular breast cancer (18). Whether the diagnosis 
of cancer in both breasts is done at the same time or at different times determines whether the 
cancer is synchronous or metachronous, respectively (19). The risk of metachronous breast 
cancer is higher than that of synchronous breast cancer, 3-13% vs. 1-5% (20). Women with 
bilateral breast cancer have poorer prognoses compared to women with unilateral breast 
cancer (20). The prognosis is considered poor if metastases start to form (21). This is because 
the disseminated cell clones are considered aggressive because they have more genetic 
alterations compared to the cells found in the primary tumor (21). 
 
The genetic landscape of breast cancer can be quite varied. In some cases the progression of 
the tumor from certain clones can be seen, but in other cases a variety of genetically divergent 
clones can be found in the tissue samples (22). One frequently found genetic alteration in 
breast cancer is loss of heterozygosity (22). Changes in the function of genes p53 and BRCA 
are also found in the formation of breast cancer (21), among many other mutations. In cases 
of metastases genetic mutations affect many genes (e.g. proto-oncogenes and tumor 
suppressor genes) and pathways, such as DNA repair pathways (21).  
 
Several treatment methods are available for breast cancer. Quandrantectomy and mammary 
segmental resection are types of surgery where only the affected regions of the breast are 
removed (18). Modified radical mastectomy, partial mastectomy and breast conserving 
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surgery are other types of surgery used for treating breast cancer (23). Other treatment 
methods also exist such as radiotherapy, chemotherapy and endocrine treatment (18, 23), 
often in combination with some type of surgery. The type of treatment depends on how early 
the cancer is detected and on the type of cancer. 
 
Breast cancer is generally diagnosed by clinical examination (18, 23), mammography or 
ultrasound (18, 20). In some cases it is diagnosed with the help of magnetic resonance 
imaging (20), because tumors might not be visible with the former methods even though 
present. In cases where there is cause to believe the presence of a tumor, biopsies are taken for 
sampling (18). Genetic diagnostics could help in making a more accurate diagnose of the type 
and severity of the cancer. 
 
2.3 FFPE samples 
FFPE samples of tissues are frequently made for the purpose of studying tissues and their 
molecular make-up (1, 3) The DNA and RNA found in the samples are often of interest (4). 
Formalin-fixation is a very frequently used method for fixing samples in histopathology (3, 
4).  Why these samples are so widely used is explained by their many good characteristics 
such as the low cost of the method, the possibility of long storage time, ease of handling and 
keeping of the quality of the samples through time (3). But most importantly, formalin 
fixation keeps samples relatively close to their in vivo morphology (4).  
 
Unfortunately formalin-fixation has some setbacks. Fixation of tissues with formalin creates 
DNA-tissue protein cross-links in the samples (6), which hinder amplification of the DNA 
(3). The cross-linking is reversible to some extent (4). The aging of FFPE samples and 
changes in the fixative pH cause fragmentation of nucleic acids (2), which results in poor 
quality of the DNA extracted from the samples. According to some researchers, for each 
decade of storage, FFPE samples go through 5-50% degradation of nucleic acids (1). Also, 
there is no standardization in the multi-stepped method of specimen preparation (6).  
 
The way FFPE specimens are specifically made varies from laboratory to laboratory, but the 
general steps are the same. The first step of the process of creating FFPE samples is fixation. 
10% formalin, which is a 2-phase fixative, is the most commonly used fixative. It consists of 
formaldehyde and water. The first phase of fixation occurs with alcohol. The second phase, 
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which is done with the assistance of aldehydes, is a cross-linking phase. After fixation comes 
paraffin embedding. (1) 
 
There are several steps involved in paraffin embedding. The first step, dehydration, involves 
moving of the specimen from an aqueous environment to an environment with alcohol. 
Clearing, which is the next step, is a subsequent removal of the alcohol and replacement with 
xylene. After clearing, comes impregnation, during which the xylene is replaced with 
paraffin. After all of these different replacement steps the tissue sample is surrounded with 
paraffin in embedding. At this point the sample is ready for sectioning with a microtome and 
long term storage. (1) 
 
The study of fragmented DNA from FFPE samples was problematic over 10 years ago (4). 
The fragmented DNA could not be examined in a reliable way. Now, during the ‘-omics’ era, 
examination of such samples is easier because of the new techniques available (4). Therefore 
interest in FFPE samples has increased. 
 
2.4 Other kinds of tissue samples 
Different kinds of tissue samples are taken from patients for histological, molecular and 
genetic analyses. Larger samples contain more DNA to study, but often only small samples 
can be taken. 
 
Biopsies are a common type of tissue sample taken from patients. There are several kinds of 
biopsies procured from tissue depending on the size and location of the atypical tissue: fine 
needle aspiration and core needle biopsies (18), and surgical biopsies 
(http://www.cancer.org/treatment/understandingyourdiagnosis/examsandtestdescriptions/forw
omenfacingabreastbiopsy/breast-biopsy-biopsy-types, 24.08.2016).  In fine needle aspiration 
a small tissue sample is aspirated into the syringe, while in core needle biopsies a hollow 
needle aspirates a narrow column of tissue into the syringe. Even though the sample volumes 
in needle biopsies are small, the samples have enough of DNA in them for analysis (13). 
Surgical biopsies require a surgical procedure, as the name suggests. Tissue samples taken by 
biopsy are sometimes frozen for later DNA studies (4). Unfortunately, most hospitals do not 
have the capacity to storage large numbers of frozen samples for the duration of years (1, 4). 
But some tissues are frozen explicitly.  
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Some tissue samples are frozen directly after their retrieval from the patient 
(http://www.amsbio.com/Tissues-Frozen-Tissue-Sections.aspx?cty=FINLAND&cur=EUR, 
24.08.2016). Such samples are frozen tissue sections. The fresh tissue samples are frozen in 
liquid nitrogen before they are cut into sections, which are then viewed. Other sample types 
remain fluid. 
 
Biofluids can be used for diagnostics. All fluids from the body, such as blood, urine and tears, 
can be studied and used for diagnostic purposes (24). The fluids and their molecular 
composition can be analyzed in vivo or uninvasively.    
  
2.5 Next-Generation Sequencing 
All useful techniques are improved in time, the same goes for sequencing. Sanger sequencing 
is referred to by the term first-generation sequencing (2, 8), and it is a form of sequencing that 
is still used today, but less. Sanger sequencing is an analogue form of sequencing (2).  
 
In Sanger sequencing there are two phases which are performed separate from each other: 
first, the synthesis, and second, the electrophoresis. During synthesis, a complementary DNA 
strand is synthesized by DNA polymerase which incorporates deoxyribonucleotide 
triphosphates (dNTPs) and dideoxyribonucleotide triphosphates (ddNTPs) into the strand 
(25), in a random fashion. When a ddNTP is attached to the strand, the synthesis of the 
complimentary strand is terminated (25). As a result, many different strands with varying 
lengths are produced and these fragments are separated by gel electrophoresis, after which 
their analysis reveals the base order of the sequence (25). Because Sanger sequencing is not 
digital, there are things that cannot be done with the method. 
 
First generation sequencing is much more limited in the information that it gives. Sanger 
sequencing cannot be used to detect all of the possible alterations found in cancer 
simultaneously, which are deletions, small insertions, nucleotide substitutions, copy number 
alterations and chromosomal rearrangements (2). It is why NGS was developed. 
 
NGS is a digital form of sequencing (2). Single molecules of DNA are used in array-like 
amplification and subsequent recognition by computer (2). The method uses over-sampling 
(2), which refers to the reading of the DNA sequence multiple times and the production of 
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many reads. Over-sampling brings an increase of sequence read-out confidence (2).  The 
technology has increased throughput (8), making it possible to sequence and analyze 
numerous samples at the same time. NGS also allows for complex analysis of DNA and 
genomes, since deletions, small insertions, nucleotide substitutions, copy number alterations 
and chromosomal rearrangements – all the things Sanger sequencing could not do 
simultaneously – can be studied at the same time. The technology has made it possible to 
study aligned sequencing reads anywhere in the genome (2). Next-generation sequencing can 
be used for many other applications as well. Different NGS methods are available on the 
market. 
 
There are different methods of sequencing with NGS. Some of the methods used are picotitre-
plate pyrosequencing, ligation-based sequencing and single-nucleotide fluorescent base 
extension (2). In general there is a set of main phases in all of the methods: template 
preparation, sequencing combined with imaging and the analysis of the sequencing data (8).  
A DNA library is made during template preparation. 
 
Template preparation includes the creation of a DNA library, which is then used as a template 
for sequencing (25). The process requires the fragmentation of genomic DNA. There are two 
kinds of templates used, clonally amplified or single-molecule templates (25). In the former, a 
DNA library is made, denatured into ssDNA, attached to beads or a solid surface and then 
finally amplified in order to increase the fluorescent signal during imaging. In the latter, 
single molecules of template are attached to a solid surface and no PCR is required. 
Sequencing and imaging follow. 
 
Sequencing and imaging of clonally amplified and single-molecule templates is different. 
After the addition of a single nucleotide or probe to the template during sequencing, the signal 
is treated differently, depending on which template is used (25). During the imaging of 
clonally amplified templates, the fluorescent signals from a batch of the same amplified DNA 
molecule are treated as one consensus signal.  If a single-molecule template is used, then each 
fluorescing nucleotide or probe gives an independent fluorescent signal. Imaging of the 
fluorescing signals occurs after each sequencing cycle. Sequencing techniques differ in the 
sequencing platforms available. 
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The techniques used for sequencing vary in the chemistry used. Cyclic reversible termination 
(CRT), sequencing by ligation, pyrosequencing and real-time sequencing are techniques 
found on the NGS market (8). NGS that uses CRT, incorporates a single modified nucleotide 
to the growing complementary strand per cycle, after which imaging occurs (8). After 
imaging, the terminating or inhibiting group and the fluorescing dye are cleaved off. After 
cleavage, a new cycle can begin. The technique is very different compared to sequencing by 
ligation. 
 
Labeled probes are used in sequencing by ligation (8). The probes attach by hybridization to 
complimentary sequences next to the primed template. The labeled probe and primer are 
attached by DNA ligase. Fluorescent imaging takes place, after which either the probes are 
removed or the primers are replaced, and a new cycle can occur.  
 
Pyrosequencing is a bioluminescent method. In pyrosequencing, the termination of DNA 
synthesis is done by limiting the amount of a single type of dNTP added (8). The DNA 
polymerase adds a nucleotide to the primer and stops. When more dNTP is added, the 
synthesis continues. When a pyrosequencing reaction occurs and pyrophosphate is released, 
the light generated is measured by a camera. The intensities are recorded as flowgrams and 
give the order of the bases in the sequence. 
 
During real-time sequencing, imaging occurs at the same time as DNA synthesis which is not 
stopped at any moment (8). In some real-time sequencing technologies, a fluorescing dye is 
used in signaling, while in others a dye-quencher group is used for emitting a signal (8). Once 
sequencing is performed, the data can be analyzed.  
 
2.6 Genotyping with qPCR 
There are different genotyping methods which utilize PCR such as long-distance PCR 
methods and inverse shifting PCR (11). Some of the methods are very labor-intensive and 
time consuming (11). The development of qPCR has made things quicker and more efficient. 
Real-time PCR techniques make it possible to follow the production of the PCR end product 
in real time. The techniques involved incorporate the use of detection probes (12). 
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The labeled detection probes used in qPCR make it possible to follow the production of the 
end product in the instant they are produced (12). The probes fluoresce when end product is 
formed. One of the labeling techniques uses the exonuclease functions of Taq DNA 
polymerase (12). A quencher dye is attached to the 5’ end of the probe and a reported dye to 
the 3’ end. When the Taq DNA polymerase begins elongation, it first cuts off the quencher 
dye with its exonuclease activity. This causes the reporter dye to fluoresce in ratio to the 
amount of produced end product. Fluorescent resonance energy transfer (FRET) probes are 
also used for end product detection. 
 
When FRET is used, two probes are utilized; one upstream and another downstream. The 
probe upstream has an excitatory dye at its 3’ end, while the probe downstream has a reporter 
dye at its 5’ end (12). The two probes hybridize during the annealing phase of PCR when 
there is end product. After hybridization the excitatory dye gives an electron to the reporter 
dye, causing it to fluoresce. The intensity of the fluorescence is then measured. Molecular 
beacons are also used in quantitative real-time PCR. 
 
There are three components to molecular beacons (12). The first component is the tagged 
probe, of which there are two. They are end-product specific and have a quencher and a 
reporter dye at opposing ends. The second component consists of two complimentary 
sequences in each probe, one on the 5’ end and one on the 3’ end, allowing for the formation 
of a “stem”. The third component is in the loop which is formed in the probe: a target specific 
sequence. The molecular beacon has an “on” and “off” position. Initially the beacon is off and 
no signal is emitted. This is when the PCR cycle is at or below annealing temperatures and the 
beacon is in a stem and loop conformation. When the stem is formed, the quencher and 
reporter dye are close to one another, resulting in no signal. When end-product formation 
begins and when an end-product molecule hybridizes with the target-specific sequence in the 
loop the beacon is turned on, the dyes are removed and a signal emitted. 
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3. Objectives 
There were two objectives to this experiment. The first objective was to test the sensitivities 
of Illumina’s MiSeq Benchtop Sequencer and Fluidigm’s BioMark HD qPCR. The second 
objective was to measure or to estimate the minimal fractions of cancer DNA that the two 
instruments could detect.  
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4. Materials and Methods 
 
4.1 Cell lines 
Two cells lines were selected for this study: prostate cancer cell line LNCaP clone FGC and 
breast cancer cell line MDA-MB-415. Both cells lines were from Tapio Visakorpi’s 
Molecular Biology of Prostate Cancer group from the University of Tampere, Finland. These 
two specific cell lines were selected, because they both contained SNVs in certain genes 
which could be targeted by Agilent’s HaloPlex Cancer Research Panel Kit (Agilent 
Technologies, Santa Clara, USA), see Table 1 in Appendix 1.  
 
Five different SNVs were selected for targeting from each cell line. Five variants per cell line 
were considered sufficient because most of the variants in the HaloPlex Cancer Research 
Panel were found in both cell lines, which would have been problematic. The SNVs were 
different, so that when SNV detection occurred, it would be clear in which cell line the 
mutation was found in. The online databases Catalogue of Somatic Mutations in Cancer 
(COSMIC) at (http://cancer.sanger.ac.uk/cosmic, 07.01.2014) and Cancer Cell Line 
Encyclopedia (CCLE) at (http://www.broadinstitute.org/ccle/home, 07.01.2014) were used to 
verify which mutated genes in the cancer panel were found in the cell lines used. 
During culture, the growth medium used for the LNCaP cells was ATCC-formulated RPMI-
1640 Medium, which was supplemented with fetal bovine serum (FBS) up to a concentration 
of 10% and 1% L-glutamine, see Appendix 2 for a list of reagents and kits used. The cells 
were detached from the flask with trypsin for subculturing. All washes were done with 
phosphate-buffered saline (PBS). The cells were incubated at a temperature of 37 °C. 
The MDA-MB-415 cell line used Leibovitz's L-15 medium with 2mM L-glutamine and was 
supplemented with 10 μg/ml insulin, 10 μg/ml glutathione and FBS, of which the last 
supplement had a final concentration of 15%. When subculturing, the cells were detached 
from the flask by scraping. All washes were done with PBS. The MDA-MB-415 cells were 
also incubated at 37 °C, but separately from the LNCaP cells in an incubator with only free 
gas exchange with the surrounding atmospheric air, because Leibovitz’s L-15 medium is not 
suitable for cells in an environment with a CO2 and air. 
 
14 
 
4.2 DNA extraction 
Qiagen QIAamp DNA Mini kit was used for DNA extraction. The LNCaP and MDA-MB-
415 cells were collected separately from their culture flasks according to the “Protocol for 
Cultured Cells in QIAamp DNA Mini and Blood Mini Handbook, third edition, June 2012”. 
A cell count was performed. The cell count was done with two methods: manually by a 
hemocytometer and digitally with Moxi Z Mini Automated Cell Counter (ORFLO 
Technologies, Ketchum, USA). Their average was used for cell number estimation to be sure 
it did not exceed the maximum number specified by the protocol, which was 5 x 10
6
 cells. 
 
After the cell count, the protocol “DNA Purification from Blood or Body Fluids (Spin 
Protocol)” which was also in the QIAamp DNA Mini and Blood Mini Handbook was used for 
the extraction of DNA. The DNA was eluted into a buffer provided by the kit. 
 
4.3 Measuring of DNA concentration 
The concentration of extracted DNA was measured with Qubit 3 fluorometer (ThermoFisher 
Scientific, Waltham, USA). The manual “Measuring of DNA with Qubit” was followed. 
4.4 Samples with varying fractions of DNA for sequencing 
Fifteen samples with different fractions of LNCaP and MDA-MB-415 DNA were made, see 
Table 1. Each sample had a combined total DNA amount of 225 ng, which was required by 
Agilent’s HaloPlex Target Enrichment System protocol. DNase-free water was used for 
making the dilutions. 
 
4.5 Agilent HaloPlex Target Enrichment System 
The protocol HaloPlex Target Enrichment System for Illumina Sequencing (Version D.5, 
May 2013) was used for making a sequencing library suitable for Illumina paired-end 
multiplex sequencing. The workflow for the protocol can be seen in Appendix 3 Figure 1. 
The protocol was followed step by step, using the reagents provided by HaloPlex Cancer 
Research Panel Kit.  
 
4.5.1 Digestion 
The 15 samples and one control were prepared for the protocol. The control was an 
Enrichment Control DNA (ECD) sample provided by Agilent, but nothing of its contents was 
disclosed. 
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Table 1. Cell line DNA mixtures for sequencing. The ratio of LNCaP and MDA-MB-415 
DNA in the samples is shown. Samples 10-15 are internal replicates.  
Sample LNCaP-% Amount of DNA 
(ng) 
MDA-MB-415-
% 
Amount of 
DNA (ng) 
1 0 0.0 100 225.0 
2 10 22.5 90 202.5 
3 20 45.0 80 180.0 
4 30 67.5 70 157.5 
5 50 112.5 50 112.5 
6 70 157.5 30 67.5 
7 80 180.0 20 45.0 
8 90 202.5 10 22.5 
9 100 225.0 0 0.0 
10 0 replicate 0.0 100 replicate 225.0 
11 10 replicate 22.5 90 replicate 202.5 
12 20 replicate 45.0 80 replicate 180.0 
13 80 replicate 180.0 20 replicate 45.0 
14 90 replicate 202.5 10 replicate 22.5 
15 100 replicate 225.0 0 replicate 0.0 
 
The genomic DNA samples were digested in eight restriction reactions A-H, see Figure 1. 
Each reaction had two different restriction enzymes. The program for the thermal cycler 
(BioRad, Hercules, USA) during the digestion was according to the protocol. 
 
 
Figure 1. Restriction reactions for gDNA. The DNA samples 1-15 and the control ECD, 
were digested in eight restriction reactions A-H, each containing two unknown restriction 
enzymes. For simplification, only one 96-well plate with samples is shown, but two plates 
were used. Modified Figure from HaloPlex Target Enrichment System Protocol for Illumina 
Sequencing, Version D.5, May 2013. 
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4.5.2 Validation of ECD Restriction Digestion 
Validation of the restriction digestion was done with 2100 Bioanalyzer (Agilent 
Technologies, Santa Clara, USA) and a High Sensitivity DNA Kit. The analysis with the 
Bioanalyzer was an electrophoretic analysis. The protocol used for the validation was 
“Agilent High Sensitivity DNA Kit Guide, G2938-90321 Rev. B, Edition 11/2013”. Only the 
digested ECD reactions were analyzed in this validation. 
 
4.5.3 Hybridization of DNA to HaloPlex Probes  
Hybridization of the digested DNA to HaloPlex probes was done. At the same time, the 
samples were indexed for sequencing by adding Indexing Primer Cassettes provided by 
HaloPlex Cancer Research Panel Kit. Indexing was done according to sample number; sample 
1 was given index #1, sample 2 was given index #2, and so forth for all 15 samples and the 
one control. During hybridization, sequencing motifs made by Illumina were automatically 
also added to the DNA fragments, see Figure 2. During hybridization the DNA probes 
directed the circularization of the targeted DNA fragments. Hybridization was done for 3 
hours in a thermal cycler, according to the appropriate program indicated by the protocol. 
 
4.5.4 Capturing the Target DNA 
During the capture-phase of the protocol, the target DNA-HaloPlex probe hybrids were 
captured. The hybrids contained biotin, which made it possible to capture them with beads 
coated with streptavidin. The Agencourt AMPure XP Kit with its beads and reagents was 
used for the capture reaction. For an optimal capture reaction, a fresh and specifically diluted 
batch of NaOH was made. Therefore, specific guidelines were used, see Appendix 4. 
 
 
Figure 2. Content of HaloPlex-Enriched Target Amplicons. All amplicons contained 
the following parts: target insert (blue), Illumina’s sequencing motifs (black), index (red) 
and library bridge PCR primers (yellow). Figure from HaloPlex Target Enrichment System 
Protocol for Illumina Sequencing, Version D.5, May 2013. 
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4.5.5 Ligation of Fragments  
The nicks in the circularized HaloPlex probe-target DNA hybrids were closed using DNA 
ligase. The samples were incubated in a thermal cycler. 
 
4.5.6 Preparation of PCR Master Mix 
A master mix was made for the PCR reaction according to the protocol. Reagents not supplied 
by the kit are mentioned in Appendix 2.  
 
4.5.7 Elution of Captured DNA 
Elution of the captured DNA libraries was done with NaOH. The target DNA was released 
from the beads during this step. 
 
4.5.8 Amplification of Captured Target Libraries 
Amplification of the captured target libraries was done with PCR (BioRad). The program 
used is shown in Table 2. 
 
 
 
Table 2. Amplification Program. The program used for the amplification of the captured 
target DNA. Segment 2 of the amplification consisted of 23 cycles. 
Segment Number of Cycles Temperature (°C) Time 
1 1 98 2 minutes 
2  98 30 seconds 
2      23 60 30 seconds 
2  72 1 minute 
3 1 72 10 minutes 
4 1 8 Hold 
 
4.5.9 Purifying of the Target Libraries 
The amplified target DNA was purified with the help of AMPure XP beads. 70% ethanol was 
used for the washes performed in this phase. Tris-acetate was used in the elution of the DNA. 
4 μl of each library was set aside for the validation of the enrichment with Bioanalyzer.  
 
4.5.10 Validation of Enriched Target DNA 
The enriched target DNA was validated with two different devices. Originally the 2100 
Bioanalyzer (Agilent Technologies) was supposed to be the only device used for validation. 
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The device did not work reliably, and so another device, LabChip GXI (PerkinElmer, 
Waltham, USA) was used to validate some of the samples.  
  
There were two purposes for sample validation. The first one was to verify that there was a 
peak between 225 and 525 bp in the electropherograms representing the amplicon. The 
second was to determine the concentration of the enriched DNA by performing peak 
integration between peaks at 175 and 625 bp. For samples with too high a concentration 
(above 10 ng/μl), 1:10 dilutions were made with water and the samples were run again. 
 
4.5.11 Pooling of DNA Samples 
Equimolar amounts of indexed sample DNA had to be pooled for sequencing. The 
concentration values from the Bioanalyzer and LabChip measurements were used. Making a 
single equimolar DNA pool was impossible, because of the range of differences in molarity, 
so therefore two separate DNA pools were made, see Table 3. Those samples which had 
higher molarities were pooled into DNA Pool 1 and samples which had low molarities were 
pooled into DNA Pool 2. The samples in DNA Pool 2 happened to be the same ones that did 
not give reliable measurement values with the Bioanalyzer and were measured with LabChip 
GXI. See Appendix 5 for an example of the calculations. 
    
After pooling the samples into DNA Pool 1, the pool went through a round of AMPure XP 
bead purification. This additional purification was done, as was suggested in the protocol, if 
any of the samples had more than 10% molarity of adapter-dimer (at 125-150 bp) in the 
electropherograms compared to the peak value. The molarity of the adapter-dimer was more 
than 10% in most cases. 
 
Pooling of samples into DNA Pool 2 was difficult. The required volume of DNA for each 
sample surpassed the amounts that were available. Since there was no time to grow more cells 
for the experiment, an improvisation was done. 5 μl of each sample was pooled together 
because their molarities were in the same range. Sample 12 was an exception; only 2.5 μl of 
DNA was pooled for the sample because it had twice the molarity of the other samples. In this 
way the pool had an average molarity of 8.3 nmol/l. The total volume for Pool 2 was 32.5 μl. 
The pool was not diluted by the addition of water. 
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Table 3. Pooling of DNA Samples. The DNA samples were pooled into two separate DNA 
pools prior to sequencing. 
DNA Pool 1 Samples DNA Pool 2 Samples 
1, 4, 6, 9, 10, 11, 13, 14, 16 2, 3, 5, 7, 8, 12, 15 
 
4.6 Sequencing with Illumina’s MiSeq Benchtop Sequencer 
A sample sheet with sample numbers and indexes was prepared using “Agilent’s HaloPlex 
Target Enrichment System-ILM” protocol. After this the DNA library and PhiX Control were 
prepared for sequencing with Illumina’s protocol “Preparing Libraries for Sequencing on the 
MiSeq, part # 15039740 Rev C August 2013”. During the sequencing run, MiSeq 
automatically sent sequencing data to BaseSpace, a cloud-based genomics data hub. 
 
DNA Pool 1 and 2 were handled separately. The DNA library was denatured and diluted to a 
final concentration of 2 nM according to the above mentioned protocol with HT1 
Hybridization Buffer from MiSeq v2 Reagent Kit. Freshly diluted NaOH was used in all of 
the steps. Immediately before sequencing of the library an additional dilution to 6 pM was 
done according to the protocol.  
A 5% PhiX spike was used as a control during sequencing. 30 μl of denatured and diluted 
PhiX control was added to 570 μl of 6 pM DNA library. Then the library was loaded into the 
MiSeq Reagent Cartridge and was ready for sequencing. 
 
Illumina’s protocol “MiSeq System User Guide Part # 15027617 Rev. H March 2013” was 
used during the setup with PR2 reagent and HT1 Buffer (from MiSeq v2 Reagent Kit). The 
above mentioned protocol was also used during the automated sequencing of the DNA 
library.  
 
The first sequencing run of Pool 1 on Illumina’s MiSeq failed. Since the run failed and no 
data could be obtained for the run, an assumption was made that the DNA library had too high 
a concentration, therefore perhaps causing over clustering of the flow cell. The assumption 
was made on the basis that the sequencing run could not be finished and because no reads 
were given by MiSeq. The ready DNA library was diluted for a second run. The dilution was 
a 1:10 dilution with water. Otherwise everything was done according to the protocol. The 
PhiX spike was kept the same, as a 5% spike. 
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The sequencing of Pool 2 failed. Since the pool was already very dilute and because there was 
no time to grow more cells for new samples, it was decided that the sequencing of Pool 1 was 
enough for this study.  
 
4.7 Analysis of Sequencing Data 
After sequencing, the data of the run was analyzed. For the data to be in such a form that it 
could be analyzed, several computational methods were used. 
  
The Illumina adaptor sequences were removed from the ends of the fastq-files by trimming. 
Each read was trimmed by 30 bases from the 5’ end to remove the adaptor. 50 bases were also 
removed from the 3‘ end in order to remove poor quality material. These values were chosen 
because the subsequent alignment worked properly. A tool called Pypette was used for 
trimming (https://github.com/annalam/pypette, 29.03.2016). See Appendix 6, for a list of the 
used scripts. 
  
A program called Bowtie2 was then used for aligning the trimmed reads to the reference 
human genome (version 19). Default parameters were used with the program. At this point the 
files were compressed .gz files. All the reads were aligned at the same time as a batch.  
 
A computational tool called SAMtools (Sequence Alignment/Map) was used for several 
computational steps prior to viewing the alignments with Integral Genome Viewer (IGV). 
This was necessary so that IGV could utilize the sorted bam-files. SAMtools View was used 
for the conversion of .sam files to .bam files. SAMtools Sort was then used to arrange the 
reads into order according to the reference genome coordinates. SAMtools Index was then 
used to index the .bam files. All SAMtools steps were combined to form a loop, in which each 
sample went through all of the different steps in an automated way. See Appendix 6 for a list 
of the used scripts. 
 
After all of the above mentioned computational processes the files were ready for viewing. 
The program IGV was used for viewing the sequencing reads. The program was downloaded 
from the internet website (https://www.broadinstitute.org/igv/; 12.08.2014). An analysis of all 
of the .bam files which contained all of the reads was done. Both .bam and .bai files were 
required for the viewing of reads. .bai files were created automatically when files were 
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converted to .bam format. The two file types were kept in the same folder even though only 
the .bam files were opened manually with IGV. IGV opens .bai files by itself at the same time 
when .bam files are manually opened. 
 
4.8 qPCR with Fluidigm’s BioMark HD 
Fluidigm’s BioMark HD quantitative real-time PCR (qPCR) was used for SNV genotyping 
the samples. The same SNVs that were looked for by sequencing were also searched for with 
qPCR genotyping. The following protocol was used for all steps: “Fluidigm Genotyping User 
Guide, SNPtype Assays for SNP Genotyping on the Dynamic Array IFCs, PN 68000098 Rev 
J1”. All reagents used during the process can be found in Appendix 2. 
 
Fluidigm’s BioMark HD uses Integrated Fluid Circuits (IFCs), see Figure 3, which make it 
possible to run many assays at the same time. In this study a 96.96 IFC was used. The assays 
and samples were combined in 9216 separate reactions due to the network of microfluidic 
channels and valves placed in the center of the IFC. The assay and sample mixing is 
automated and occurs in the BioMark HD. 
 
 
Figure 3. Integrated Fluid Circuit. On the left 
are the inlets for the tagged assays and on the 
right the inlets for the samples. The microfluidic 
channel and valve network is in the IFC’s 
center. Figure from “Fluidigm Genotyping User 
Guide, SNPtype Assays for SNP Genotyping on 
the Dynamic Array IFCs, PN 68000098 Rev 
J1”. 
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4.8.1 Making Primers for the SNPtype Genotyping Assay 
The primers for the genotyping process were designed by Fluidigm’s D3TM Assay Design. 
The manual “D3TM Assay Design, PN 100-6812 REV. A2” was used for making the allele-
specific targets. The target sequences were given to Fluidigm in the form “80 bp + SNV + 80 
bp”, see Appendix 7. Targets for Primers. The finished primers included tags. Universal 
probes were used. 
  
4.8.2 Samples with Varying Fractions of DNA for qPCR 
The same samples that were used for sequencing were also used for the qPCR reactions. The 
samples contained 60 ng of DNA in a volume of 2.5 μl, according to the requirements of the 
protocol, see Table 4. For an example of the calculations refer to Appendix 5.  
 
4.8.3 Preparing SNPtype Assay Mixes and Sample Mixes 
Assay Mixes, which included SNPtype Assay Allele-Specific Primers (ASP) 1 and 2, were 
mixed with DNA Suspension Buffer for all of the 15 samples. A separate Assay Pre-Mix was 
made with 2X Assay Loading Reagent and PCR-certified water. These two mixes were 
combined according to the protocol to form a 10X Assay Mix. 
  
Table 4. Cell line DNA mixtures for qPCR. The ratio of LNCaP and MDA-MB-415 DNA 
in the samples. Samples 10-15 are internal replicates.  
Sample LNCaP-% Amount of DNA 
(ng) 
MDA-MB-415-% Amount of DNA 
(ng) 
1 0 0.0 100 60.0 
2 10 6.0 90 54.0 
3 20 12.0 80 48.0 
4 30 18.0 70 42.0 
5 50 30.0 50 30.0 
6 70 42.0 30 18.0 
7 80 48.0 20 12.0 
8 90 54.0 10 6.0 
9 100 60.0 0 0.0 
10 0 replicate 0.0 100 replicate 60.0 
11 10 replicate 6.0 90 replicate 54.0 
12 20 replicate 12.0 80 replicate 48.0 
13 80 replicate 48.0 20 replicate 12.0 
14 90 replicate 54.0 10 replicate 6.0 
15 100 replicate 60.0 0 replicate 0.0 
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A Sample Pre-Mix was made according to the protocol with Biotium 2X Fast Probe Master 
Mix, SNPtype 20X Sample Loading Reagent, SNPtype Reagent, ROX and PCR-certified 
water. The Sample Pre-Mix was added to 2.5 μl of each DNA sample according to the 
protocol to form the Sample Mix. 
 
4.8.4. Priming and Loading the Dynamic Array IFC 
The 96.96 Dynamic Array IFC was placed into Fluidigm’s IFC Controller HX for priming. 
The “Prime (138x)” script was run.  After priming, 10X Assay Mix was dispensed in 4 μl 
aliquots with a multichannel pipette into the assay inlets on the IFC. 5 μl aliquots of each 
Sample Mix were dispensed on the IFC’s sample inlets. Loading of the assays and samples 
into the IFC was done by placing the IFC into the IFC Controller HX and by selecting the 
“Load Mix (138x)” script. 
 
4.8.5. Thermal Cycling Protocol 
Once the assays and samples were loaded on the IFC, it was removed and transferred to 
Fluidigm’s BioMark HD FC1 Cycler for PCR. The protocol chosen was “Thermal cycling 
protocol SNPtype 96x96 bv1”, see Appendix 8. Table 1. The probes for the PCR reaction 
were selected: SNPtype-FAM and SNPtype-HEX. The following settings were also selected: 
genotyping application, ROX passive reference and auto exposure for the camera. 
 
4.9 Analysis of PCR data 
Fluidigm’s SNP Genotyping Analysis software was used to analyze the qPCR run data. The 
genotyping protocol was followed for setting up sample and assay information. During the 
setup of assay information, the primers were set as follows: ASP-1 non-mutated primer 
tagged with FAM (X-axis) and ASP-2 SNP primer tagged with HEX (Y-axis). The default 
confidence threshold of 65 was used. The data normalization method chosen was SNPtype 
normalization. The computer software compared the relative fluorescence of the tagged 
samples. After the initial analysis, a second round of analysis was performed, in which the 
confidence threshold was decreased to 50 in order to make SNV detection more sensitive.  
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5. Results 
 
5.1 Agilent HaloPlex Target Enrichment System 
The enrichment system had several phases with results. 
 
5.1.1 Validation of Restriction Digestion 
The electrophoretic run of the validation of restriction digestion is summarized in the Figure 
below, see Figure 4. Due to technical problems, the ladder used for the analysis did not show  
up in the correct scale. The bands visible in the ECD restriction samples were almost as they 
should be, when compared to the example of a successful electrophoresis run in the protocol; 
3 bands of varying size, which are the results of digestion by two restriction enzymes. It was 
not possible to determine the correct size of the bands, because of the erroneous ladder 
scaling. Samples 4 and 6 were not accurate because the higher marker used was not found. 
Sample 4 had the correct number of bands, but sample 6 did not. Lane 9 contained the same 
marker as lanes 10 and 11, but it should have contained undigested ECD. 
 
5.1.2 Validation of Enriched Target DNA 
The amplicon validation results from the Bioanalyzer can be seen in Appendix 9. Figures 1-
25. Validations of samples 1, 4, 7, 12, 13 and 14 looked the best; see Appendix 9. Figures 1, 
8, 12, 17, 19 and 21 respectively. Correct amplicon size was approximately between 225 and 
525 bp. Otherwise the electropherograms did not have clear peaks in the correct range, 
indicating absence of material in the samples. Most samples had prominent peaks at 125 bp. 
These latter peaks indicated the formation of adapter-dimer.  
 
See Appendix 10. Table 1, for the measured concentration for each sample. The values for 
those samples which were most reliable were accepted for further use, see Appendix 10 
Table 2.  
 
The amplicon validation results from LabChip GXI can be seen in Appendix 11. Figures 1-7. 
As with the Bioanalyzer results, the electropherograms produced by LabChip did not have 
clear peaks in the range of 225-525 bp. Each sample also had a peak at 125-150 bp, indicating 
an adapter-dimer. See Appendix 12. Table 1 for the measured concentrations and molarities 
of the samples validated by LabChip. 
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Figure 4. Enrichment control DNA electrophoresis results. The lane designated as L 
contained the 50 bp DNA ladder. Lanes 1-8 contained the 8 ECD digestion reactions A-
H. Lanes 9-11 contained marker. The green bands represented the lower marker and the 
purple bands the higher marker. The higher markers for reactions D (lane 4) and F (lane 
6) were not found. 
 
5.2 Run Data from MiSeq Benchtop Sequencer 
The run data sent to BaseSpace was used for assessing the performance of the sequencing run. 
Appendix 13. Table 1 shows that 19, 141, 716.0 reads were produced during sequencing. 
80% of the reads aligned with the samples. The number of aligned reads for each sample can 
also be seen in Appendix 13. Figure 1. According to the figure, sample 4 (30% LNCaP DNA 
and 70% MDA-MB-415 DNA) had the largest amount of reads align with it, 18.8% of all 
reads. Sample 16 (Control DNA) had the smallest amount of reads align with it, only 2.1%. 
 
The QScore distribution plot shows the quality score distribution of the bases, see Appendix 
13. Figure 2. 74.0% of the bases have a quality score of over Q30, meaning that 74% of bases 
have a 0.1% chance of error. The coverage (C) of the sequencing run was calculated to be 1 
797. The calculations are seen in Appendix 13. Theoretically the coverage was 1 797, but 
some bases were covered more and some less.   
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5.3 Sequencing Results 
After the computational manipulation of the raw sequencing data, the data from DNA Pool 1 
was viewed with IGV. See Appendix 14. Figure 1 for the sequencing call map. An example 
of viewing a sample and one of its SNVs with IGV, see Appendix 14. Figure 2. 
 
Out of the 10 SNVs that were searched for, 4 were found: AR and PIK3R1 (from LNCaP), 
and MAP2K4 and CSF1R (from MDA-MB-415). Each SNV was found in the smallest 
fraction containing that particular cell line, which was a fraction of 10%. A 10% fraction 
contained 22.5 ng of DNA. The SNVs were also found in all consecutive fractions up to the 
100% fraction, which contained 225.0 ng of DNA.  
 
5.4 qPCR Results 
See Appendix 14. Figure 3, for the call map of the SNV genotyping with Fluidigm. 8 out of 
the 10 SNVs were found: AR, PIK3R1 and SMO (from LNCaP) and ALK, BRAF, MAP2K4, 
CSF1R and ERBB4 (from MDA-MB-415). The smallest fraction with a SNV detected was 
20%. A 20% fraction contained 12.0 ng of DNA.  
 
Not all SNVs were detected systematically from 20% onward. Detection became more regular 
at 50% for the SNVs in the MDA-MB-415 cell line. A 50% fraction was equivalent to 30.0 ng 
of DNA. SNVs in the LNCaP cell line were not detected regularly until fractions with 70% of 
LNCaP DNA. A 70% fraction was equivalent to 42.0 ng of DNA. All of the above values 
were from analysis with the default confidence threshold of 65. 
 
When the confidence threshold was decreased to 50, making detection more sensitive, the call 
information changed slightly. Some No Calls changed to SNVs, XX (homozygous non-
mutated) or YY (homozygous mutated). These changes were distributed evenly in the call 
map, making no difference in the final detection sensitivity of the SNVs.  
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6. Discussion 
The results from sequencing and qPCR were very different, see Appendix 14. Illumina’s 
MiSeq was able to detect four SNVs out of ten. If a SNV was detected, it was detected in all 
the fractions with the cell line containing the mutation. The smallest fraction of DNA detected 
contained 22.5 ng of DNA. However, six remaining SNVs were not found in any of the 
samples. Fluidigm’s BioMark HD was able to find a total of eight SNVs from the samples, 
but not systematically. The smallest fraction of DNA detected by Fluidigm contained 12.0 ng. 
 
The results from sequencing with MiSeq are not encouraging. All ten SNVs searched for in 
this study are known variants and should have been found to at least some degree in the 
samples. Only four SNVs were detected from the following genes AR and PIK3R1 from the 
LNCaP cell line, and MAP2K4 and CSF1R from the MDA-MB-415 cell line, see Figure 1 of 
Appendix 14. These four SNVs were visible in all samples, indicating that DNA from both 
cell lines was present during sequencing. The SNVs that are absent are systematically absent 
from all sequenced samples and produced no reads. This suggests that something happened 
before sequencing, during the enrichment and targeting phases of the HaloPlex Target 
Enrichment System protocol. 
  
The HaloPlex Target Enrichment System protocol, which was used for making a DNA 
library, included many phases in which the samples were treated en masse, meaning they 
were handled as a group. No individual treatment was performed, such as adding primers for 
each target. This means that if a phase had gone wrong during the protocol, it would be 
visible in all of the samples. If the hybridization of the targets had been problematic in 
general, none of the targets would have hybridized or hybridization would have randomly 
occurred, but such is not the case. Four SNVs were systematically hybridized. The same logic 
goes for the targeting. A problem in targeting would have also been visible as no targeting 
occurring or something being targeted in random. 
 
The probable absence of DNA from the samples is supported by the electropherograms of the 
samples, see Appendices 9 and 11. According to the electropherograms, samples 1, 4, 12, 13 
and 14 contained some DNA, as seen in the amplicon peaks visible, unlike most of the other 
samples. The high peak at 125-150 bp, which is visible for almost all samples, is not an 
amplicon peak, but rather a peak indicating adapter dimer. 
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All of this suggests that the missing SNVs, were not targeted by the Agilent’s HaloPlex 
Cancer Research Panel. According to Agilent and their enrichment protocol “HaloPlex probes 
hybridize selectively to fragments from target regions.” Before beginning the enrichment 
protocol, an inquiry was made to Agilent concerning the content of the target regions: would 
the specific SNVs in this study be targeted? The answer given by Agilent was that the most 
common variants in cancer could be detected by the kit. When more information about the 
targeting of the specific SNVs was asked for, no information could be given because it would 
have been commercial secret infringement. It is possible that the variants searched for in this 
study, were not included as possible targets in the panel, if they were not part of the list of 
most common variants. 
Another thought for why some variants were not visible, is that perhaps some genetic 
variation occurred during cell culture. However this idea does not hold, because the same 
absence of variants should have been visible in the qPCR genotyping results as well, since the 
method was used after sequencing. 
 
It is not possible that the washing away of samples during the targeting protocol is a reason 
for the missing variants. If some DNA were washed away, it would be visible as entire 
samples missing all sequencing reads and variants, which is not the case. The results from 
genotyping with Fluidigm’s BioMark HD were better. 
 
The qPCR with BioMark HD was able to detect eight out of ten SNVs, see Figure 3 in 
Appendix 14. The SNVs in ABL1 and NOTCH1 were not detected. It is possible that some 
pipetting errors occurred during the addition of these two particular assays onto the 96-well 
plate which was used during genotyping. This would seem likely, because the call map shows 
that No Call-results were very frequent in all samples, not just a few. 
 
The detection of the found SNVs was not systematic throughout the different fractions. Even 
though 12.0 ng of DNA were detected in 20% DNA fractions, the detection occurred 
infrequently. Systematic detection was made only from samples with larger fractions with 
more than 30.0 ng of DNA.  
 
Both genotyping methods were performed a single time, except for the actual sequencing of 
the DNA pool. This was because of a set deadline for the study. If there had not been such a 
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deadline, it would have been possible to optimize both methods, resulting in potentially better 
results. 
 
When comparing NGS and PCR-based methods, the former is able to produce large quantities 
of data compared to the latter (5). The large quantity of reads for each target area in 
sequencing makes sequencing somewhat more reliable. This is because a SNV will show up 
frequently in the reads. All reads can be seen individually and they can be compared, which is 
something that cannot be done with the qPCR genotyping method. The qPCR method runs 
each assay a single time, unless there are internal replicates on the same IFC, and gives a 
single call result. The only comparison that can be made is comparing the automatic call to 
the final call made by the analysis software. The two are not necessarily the same. If they are 
not the same, the final call could change if the confidence threshold is decreased. In this way, 
an assay can have an increased rate confidence, but it cannot be compared to the confidence 
which thousands of reads bring from NGS sequencing. 
 
The two SNV genotyping methods cannot be compared properly based on the results of this 
study, leaving this study inconclusive. Nothing can be said about the detection sensitivity of 
Illumina’s MiSeq because the steps preceding sequencing were erroneous in some part. 
Fluidigm performed better, but even it did not give good results. With the results at hand 
however, it must be said that qPCR with Fluidigm’s BioMark HD seems to be more sensitive 
and reliable than NGS with Illumina’s MiSeq. 
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7. Conclusions 
Fluidigm’s genotyping with qPCR is more sensitive than sequencing with Illumina’s MiSeq 
in the detection SNVs. Fluidigm’s BioMark HD is able to detect SNVs from 20% DNA 
fractions, which represents 12.0 ng of DNA, but infrequently. More reliable detection occurs 
in DNA fractions of 70-80%, representing 42.0-48.0ng of DNA. MiSeq is able to detect SNVs 
from samples with a 10% fraction of DNA, which represents 22.5 ng of DNA, but the method 
only detected four out of ten SNVs.  
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9. Appendices 
Appendix 1. HaloPlex Targeted Genes 
  
Table 1. Targeted genes. Genes in cell lines LNCaP and MDA-MB-415, which were 
targeted by HaloPlex Cancer Panel Kit. Targeted SNVs are shown with their coordinates, 
along with affected amino acid and mutation type. 
Prostate cancer cell line LNCaP with 
targeted SNVs 
Breast cancer cell line MDA-MB-415 with 
targeted SNVs 
ABL1 
Coordinates: 9:133,759,986-133,759,986 
N770S, A>G substitution 
ALK 
Coordinates: 2:29,940,524-29,940,524 
P236R, G>C substitution 
AR 
Coordinates: X:66,943,552-66,943,552 
T878A, A>G substitution 
BRAF 
Coordinates: 7:140,549,931-140,549,931 
P74A, G>C substitution 
NOTCH1 
Coordinates: 9:139,413,143-139,413,143 
S333S, C<T substitution 
MAP2K4 
Coordinates: 17:12,028,636-12,028,636 
S291*, C>A substitution (nonsense) 
PIK3R1 
Coordinates: 5:67,592,099-67,592,099 
R639*, C>T substitution (nonsense) 
CSF1R 
Coordinates: 5:149,433,643-149,433,643 
Q970*, G>A substitution (nonsense) 
SMO 
Coordinates: 7:128,845,520-128,845,520 
C273R, T>C substitution 
ERBB4 
Coordinates: 2:212,522,511-212,522,511 
W638*, C>T substitution (nonsense) 
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Appendix 2. List of Reagents and Kits Used 
 
Cell culture 
RPMI 1640 cell culture medium (Lonza, Basel, Switzerland) 
Leibovitz's L-15 medium for cell culture (Sigma-Aldrich, St. Louis, USA) 
 
DNA extraction 
Qiagen QIAamp DNA Mini kit (Qiagen, Hilden, Germany) 
 
Measuring of DNA concentrations with Qubit 
dsDNA BR reagent (ThermoFisher Scientific, Waltham, USA) 
dsDNA BR Buffer (ThermoFisher Scientific, Waltham, USA) 
Standard 1 (ThermoFisher Scientific, Waltham, USA) 
Standard 2 (ThermoFisher Scientific, Waltham, USA) 
 
Agilent HaloPlex Target Enrichment System 
Validation of Restriction Digestions 
2100 Bioanalyzer Platform High Sensitivity DNA Kit (Agilent Technologies, Santa Clara, 
USA) 
Capturing the Target DNA 
Agencourt AMPure XP Kit, 60 ml (Beckman Coulter Genomics, Danvers, USA) 
2M Acetic acid (Sigma-Aldrich, St. Louis, USA) 
10 M NaOH, molecular biology grade (Sigma-Aldrich, St. Louis, USA) 
PCR Master Mix 
Herculase II Fusion Enzyme with dNTPs (100 mM; 25 mM for each nucleotide, 200 
reactions), (Agilent Technologies, Santa Clara, USA) 
2M Acetic acid (Sigma-Aldrich, St. Louis, USA) 
Purifying of the Target Libraries 
100% Ethanol, molecular biology grade (Sigma-Aldrich, St. Louis, USA) 
10 mM Tris-acetate, pH 8,0 (Merck, Darmstadt, Germany) 
 
Preparing Libraries for Sequencing on MiSeq 
MiSeq v2 Reagent Kit (Illumina, San Diego, USA) 
MiSeq v2 Reagent Kit 300 cycles PE-Box (Illumina, San Diego, USA) 
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10 M NaOH, molecular biology grade (Sigma-Aldrich, St. Louis, USA) 
Tris-Cl 10 mM, pH 8.5 with 0.1% Tween 20 ( Tris-Cl from Merck, Darmstadt, Germany 
Tween 20 from Sigma-Aldrich, St. Louis, USA) 
 
Sequencing with MiSeq 
MiSeq v2 Reagent Kit (Illumina, San Diego, USA) 
MiSeq v2 Reagent Kit 300 cycles PE-Box (Illumina, San Diego, USA) 
PhiX Control (Illumina, San Diego, USA) 
 
qPCR with BioMark HD 
Biotium Fast Probe Master Mix (Biotium, Hayward, USA) 
Qiagen 2x Multiplex PCR Master Mix (Qiagen, Hilden, Germany) 
DNA Suspension Buffer, 10 mM Tris, pH 8.0, 0.1 mM EDTA (TEKnova, Helsinki, Finland) 
SNPtype Genotyping Reagent Kit 96.96 (Fluidigm, South San Francisco, USA) 
SNPtype Assay Allele-Specific Primers (ASP) Plate, 100 μM ASP1/100 μM ASP2 (Fluidigm, 
South San Francisco, USA) 
SNPtype Assay Locus-Specific Primer (LSP) Plate, 100 μM (Fluidigm, South San Francisco, 
USA) 
50X ROX (ThermoFisher Scientific, Waltham, USA) 
 
  
36 
 
Appendix 3. Workflow of Sample Preparation for HaloPlex Target-Enrichment Protocol 
 
 
 
 
Figure 1. Workflow of sample preparation for HaloPlex target-enrichment 
sequencing. An indexed library was made for all the samples with the use of 
Illumina paired-end sequencing motifs. gDNA fragment circularization occurred as 
the result of hybridization between the gDNA and Illumina’s motifs. The 
biotinylated probe DNA was captured with the help of streptavidin-coated magnetic 
beads, after which amplification of DNA was performed. The target-enriched 
samples were then ready for sequencing. Figure from HaloPlex Target Enrichment 
System Protocol for Illumina Sequencing, Version D.5, May 2013. 
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Appendix 4. Dilution Series for NaOH 
 
10 M NaOH to 1 M NaOH 
10 mol/l x X = 1 mol/l x 1 ml 
X = 
     
  
   
X = 0.1 ml = 100 μl 
 
   
 
1 M NaOH to 100 mM NaOH 
1 mol/l x X = 0.1 mol/l x 1 ml 
X = 
       
 
   
X = 0.1 ml = 100 μl 
 
 
 
100 mM NaOH to 50 mM NaOH 
100 mmol/l x X = 50 mmol/l x 1 ml 
X = 
      
   
   
X = 0.5 ml = 500 μl 
 
 
 
  
100 μl 10 M NaOH + 900 μl H2O 
100 μl 1 M NaOH + 900 μl H2O 
500 μl 100 mM NaOH + 500 μl 
H2O 
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Appendix 5. Calculations 
 
Sample preparation for sequencing 
Example of calculations for sample 2 preparation, with 10% LNCaP DNA and 90% MDA-
MB-415 DNA. 
 
22.5 ng of LNCaP DNA and 202.5 ng DNA were required for sample 2. 
 
LNCaP 
C (LNCaP) = 49 000 ng/ml 
         
       
 = 
   
 
 
X = 0.000459 ml = 0.459 μl = 0.5 μl contained 22.5 ng of LNCaP DNA 
 
MDA-MB-415 
C (MDA-MB-415) = 8 940 ng/ml 
        
        
 = 
   
 
 
X = 0.0226 ml = 22.6 μl contained 202.5 ng of MDA-MB-415 DNA 
 
DNA dilution 
C1V1 = C2V2 
 
V1 = 0.5 μl LNCaP + 22.6 μl MDA-MB-415 = 23.5 μl 
C1 = 
        
       
 = 9.5 ng/μl 
C2 = 5.0 ng/μl (Defined by HaloPlex Target Enrichment System protocol) 
V2 = 
   
  
  
          
         
 = 44.65 μl end volume 
 
Addition of water: 
44.65 μl – 23.5 μl = 21.0 μl of water was added 
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Pooling of DNA Samples 
Example of calculations for DNA Pool 1 with sample 1 with 0% of LNCaP DNA and 100% 
MDA-MB-415 DNA: 
 
C1V1 = C2V2 
C2 = 2 nM (according to Illumina sequencing protocol)  
V2 = 240 μl (the final volume of DNA Pool 1) 
 
V1 = 
    
  
  
             
       
                  
 
The total volume of DNA Pool 1 samples added together was 170.7 μl. Distilled water was 
added up to the final volume of 240 μl. 
 
Sample preparation for qPCR 
Example of calculations for sample 2 with 10% LNCaP DNA and 90% of MDA-MB-415 
DNA: 
C1V1 = C2V2 
C2 = 60 ng/2.5 μl = 24 ng/μl 
 
C2 (LNCaP) = 0.10 x 24 ng/μl = 2.4 ng/μl 
C2 (MDA-MB-415) = 0.90 x 24 ng/μl = 21.6 ng/μl 
 
C1 (LNCaP) = 49.0 ng/μl 
 
V1 = 
    
  
  
   
  
  
         
          
 = 0.122 μl LNCaP DNA 
 
C1 (MDA-MB-415) = 30.0 ng/μl 
 
V1 = 
    
  
  
    
  
  
         
          
 = 1.8 μl MDA-MB-415 DNA 
 
0.12 μl LNCaP DNA + 1.8 μl MDA-MB-415 DNA + 0.58 μl H2O = 2.5 μl sample volume 
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For pipetting ease the volumes above were multiplied by 3.5: 
 
0.42 μl LNCaP DNA + 6.3 μl MDA-MB-415 DNA + 2.03 μl H2O 
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Appendix 6. Scripts Used During Computational Modification of Sequencing Data. 
 
Trimming 
The following scripts were used during trimming: 
 
Example of trimming with sample 4 (30% LNCaP DNA and 70% MDA-MB-415 DNA): 
 
Trimming of 3’ end: 
-3 50 -1 LNCaP-30-MDA-70.fastq 
Trimming of 5’ end: 
-5 30 -1 LNCaP-30-MDA-70.fastq 
 
fasta trim LNCaP-30-MDA-70.fastq100 
 
SAMtools 
The following scripts were part of a loop using different SAMtools commands: 
 
Example with X denoting a single file representing one sample: 
 
SAMtools View: 
 
#|/bin/bash 
for X in *.SAM 
 do 
  samtools view –b –h –S $X > ${X/.sam/.bam} 
   done 
 
SAMtools Sort: 
 
for X in *.bam 
 do 
  samtools sort $X ${X/.bam/.sorted} 
   done 
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SAMtools Index: 
 
for X in *.sorted.bam 
 do 
  samtools index $X 
   done 
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Appendix 7. Targets for Primers 
 
LNCaP cell line 
 
Gene: ABL1, coordinate 9:133759986-133759986, A>G substitution 
 
Sequence for coordinates chr9:133759906-133760066 
GGGAAGACAGTTTGACTCGTCCACATTTGGAGGGCACAAAAGTGAGAAGCCGGC
TCTGCCTCGGAAGAGGGCAGGGGAGA[A/G]CAGGTCTGACCAGGTGACCCGAGG
CACAGTAACGCCTCCCCCCAGGCTGGTGAAAAAGAATGAGGAAGCTGCTGATGA
GG 
 
Gene: AR, coordinate X:66943552-66943552, A>G substitution 
 
Sequence for coordinates chrX:66943472-66943632
 AGCAGAGGCCACCTCCTTGTCAACCCTGTTTTTCTCCCTCTTATTGTT
CCCTACAGATTGCGAGAGAGCTGCATCAGTTC[A/G]CTTTTGACCTGCTAATCAAG
TCACACATGGTGAGCGTGGACTTTCCGGAAATGATGGCAGAGATCATCTCTGTGC
AAGTG 
 
Gene: NOTCH1, coordinate 9:139413143-139413143, G>A substitution. 
  
Sequence for coordinates chr9:139413063-139413223
 TCGCAGTAGAAGGAGGCCACACGGTCATGGCAGGTGGCGCCGTGGA
AGCAGGCGGCGCTGGCACAGTCATCAATGTTCTC[G/A]CTGCAGTCCTCACCAGTC
CAGCCGTTGACACACACGCAGTTGTAGCCACCGTGGGTGTTGTGGCAGGTCCCGC
CGTTCTG 
 
Gene: PIK3R1, coordinate 5:67592099-67592099, C>T substitution 
 
Sequence for coordinate chr5:67592019-67592179
 ATGATGAAGATTTGCCCCATCATGATGAGAAGACATGGAATGTTGGA
AGCAGCAACCGAAACAAAGCTGAAAACCTGTTG[C/T]GAGGGAAGCGAGATGGC
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ACTTTTCTTGTCCGGGAGAGCAGTAAACAGGGCTGCTATGCCTGCTCTGTAGTGT
ATGTATCT 
 
Gene SMO, coordinate 7:128845520-128845520, T>C substitution 
 
Sequence for coordinates chr7:128845440-128845600
 CTCTCTTCTAGGCCACATTCGTGGCTGACTGGCGGAACTCGAATCGC
TACCCTGCTGTTATTCTCTTCTACGTCAATGCG[T/C]GCTTCTTTGTGGGCAGCATT
GGCTGGCTGGCCCAGTTCATGGATGGTGCCCGCCGAGAGATCGTCTGCCGTGCAG
ATGGC 
 
MDA-MB-415 cell line 
 
Gene: ALK, coordinate chr2:29940524-29940524, G>C substitution 
 
Sequence for coordinates chr2:29940444-29940604
 CATATCGGCTGCGATGAGACAGGAAAGGGAAGGAGTCTTTCATTATC
CAGGTGAGATTCCATGTAAAATAATCAGGAGAA[G/C]GAGATGGCATGTTTGTTG
GTGATTCCAAGGAGCTATGACCTGGACATAAAAATAAAGAAAACACTGATCCAT
GTGCTTGG 
 
Gene: BRAF, coordinate chr7:140549931-140549931, G>C substitution 
 
Sequence for coordinates chr7:140549851-140550011
 TTTTTATAAGTTCATTTTTTTTCTTTTCAAAATTACTAGATATGATACT
CAAAAGCTTACCTCCAGATATATTGATGGTG[G/C]ATTATGCTCCCCACCAAATTT
GTCCAATAGGGCCTCTATATGTTCCTGTGTCAACTTAATCATTTGTTTGATATTCC
ACA 
 
Gene: MAP2K4, coordinate chr17:12028636-12028636, C>A substitution 
 
Sequence for coordinates chr17:12028556-12028716
 GCCTATTCCTTGAGTGTAAGGCAATTAATAACTTACACTTGTCTTTAT
GTTCCAGCCTGAAAGAATAGACCCAAGCGCAT[C/A]ACGACAAGGATATGATGTC
45 
 
CGCTCTGATGTCTGGAGTTTGGGGATCACATTGGTATGTTTATGCTGATTCAACCT
TGCCA 
 
Gene: CSF1R, coordinate chr5:149433643-149433643, G>A substitution 
 
Sequence for coordinates chr5:149433563-149433723
 GTGTCGCCCCATCCATGGAGGAGTTGAAGTTTGGAGGAGGGGAGAG
TGGTACTCCCTGTCGTCAACTCCTCAGCAGAACT[G/A]ATAGTTGTTGGGCTGCAG
CAAGGGCTGGGCGATATCCCCTTGCTCGCAGCAGGTCAGGTGCTCACTAGAGCTC
TCCTCCT 
 
Gene: ERBB4, coordinate chr2:212522511-212522511, C>T substitution 
 
Sequence for coordinates chr2:212522431-212522591
 AACTAGGAAAGGATTTGAGCGACAAAATGGAAACATGGTAGATGTT
ACCTAGCATGTTGTGGTAAAGTGGAATGGCCCGT[C/T]CATGGGTAGTAAATGCA
GTCATGACTAGTGGGACCGTTACACCTGCAGGCAATTACAGAACAGAAAACATC
ATTCTCCAT 
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Appendix 8. PCR Program for Genotyping 
 
The genotyping program used by Fluidigm’s BioMark HD had the phases specified in Table 
1. 
 
Table 1. PCR program. The SNP-genotyping PCR program used during SNP genotyping. 
Thermal Cycling 
Conditions 
Cycles Temperature Time 
Thermal Mix 1 cycle of: 70 °C 
25°C 
30 min 
10 min 
Hot Start 1 cycle of: 95 °C 5 min 
Touchdown (from 
64.0-61.0 °C, 
dropping 1 °C per 
cycle) 
1 cycle of: 
 
 
1 cycle of: 
 
 
1 cycle of: 
 
 
1 cycle of: 
95 °C 
64 °C 
72 °C 
95 °C 
63 °C 
72 °C 
95 °C 
62 °C 
72 °C 
95 °C 
61 °C 
72 °C 
15 sec 
45 sec 
15 sec 
15 sec 
45 sec 
15 sec 
15 sec 
45 sec 
15 sec 
15 sec 
45 sec 
15 sec 
Additional PCR 
cycles 
34 cycles of: 95 °C 
60 °C 
72 °C 
15 sec 
45 sec 
15 sec 
Cool 1 cycle of: 25 °C 10 sec 
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Appendix 9. Validation of Amplicon Size with 2100 Bioanalyzer 
 
Figures 1-25 show all the electropherograms and electrophoresis run results for samples 1 to 
16. Any additional runs are also shown directly after the initial runs. The peak values are 
indicated for each electropherogram. Correct amplicon size was approximately between 225 
and 525 bp. The lower marker (green) is at 35 bp and the higher marker (purple) is at 10 380 
bp. Necessary dilutions were done in a 1:10 ratio. 
 
Sample 1 
 
Figure 1. Sample 1 electropherogram. Peak Value: 202 bp. The electrophoretic run 
indicates that most of the product is the amplicon of 202 bp.  
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Sample 2 
 
Figure 2. Sample 2 electropherogram. Peak Value: 307 bp. The peak at 71 bp is adapter-
dimer. The baseline of the run was not normal and the lower marker had to be manually set at 
35 bp. No clear band is visible. 
 
Sample 2 diluted 
 
Figure 3. Sample 2 diluted electropherogram. Peak value: 335 bp. The peak at 131 bp is 
adapter-dimer. The amplicon is not clear enough in the electrophoretic run.  
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Sample 2 undiluted 
 
Figure 4. Sample 2 undiluted electropherogram. Peak value: 334 bp. The peak at 132 bp is 
adapter-dimer. The electrophoretic run shows a single dark band, but it is not the amplicon, 
but the adapter-dimer.  
 
Sample 3 
 
Figure 5. Sample 3 electropherogram. Peak value: 242 bp. The peak at 149 bp is adapter-
dimer. The lower marker had to be set manually. The dark band in the electrophoretic run is 
adapter-dimer. 
 
 
 
 
 
50 
 
Sample 3 diluted (2
nd
 run) 
 
Figure 6. Sample 3 diluted electropherogram. The sample cannot be detected. The peak at 
133 is adapter-dimer. The lower marker had to be set manually. The baseline is off. The 
validation was not successful. 
 
Sample 3 diluted (3
rd
 run) 
 
Figure 7. Sample 3 undiluted electropherogram. Peak value: 212 bp. The peak at 132 bp is 
adapter-dimer. The baseline is off. The band in the electrophoretic run is adapter-dimer. The 
validation was not successful. 
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Sample 4 
 
Figure 8. Sample 4 electropherogram. Peak value: 205 bp. The peak at 139 bp is adapter-
dimer. The amplicon is visible on the electrophoretic run. 
 
Sample 5 
 
Figure 9. Sample 5 electropherogram. Peak value: 423 bp. The peak at 131 bp is adapter-
dimer. The baseline of the electropherogram was off. The validation was not successful. 
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Sample 5 undiluted 
 
Figure 10. Sample 5 undiluted electropherogram. Peak value: 340 bp. The peak at 134 bp 
is adapter-dimer. Neither of the dark bands in the electrophoretic run are amplicons.  
 
Sample 6 
 
Figure 11. Sample 6 electropherogram. Peak value: 273bp. The peak at 130 bp is adapter-
dimer. The band in the electrophoretic run represents the dimer. 
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Sample 7 
 
Figure 12. Sample 7 electropherogram. Peak value: 231 bp. The peak at 128 bp is adapter-
dimer. Both dimer and amplicon are visible in the electrophoretic run. 
 
Sample 8 
 
Figure 13. Sample 8 electropherogram. Peak value: 321 bp. The peak at 129 bp is adapter-
dimer. The electrophoretic run indicates that there is mostly adapter-dimer. 
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Sample 9 
 
Figure 14. Sample 9 electropherogram. Peak value: 266 bp. The peak at 128 bp is adapter-
dimer. The electrophoretic run indicates that there is mostly adapter-dimer. 
 
Sample 10 
 
Figure 15. Sample 10 electropherogram. Peak value: 261 bp. The peak at 160 bp is adapter-
dimer. The electrophoretic run indicates that there is mostly adapter-dimer. 
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Sample 11 
 
Figure 16. Sample 11 electropherogram. Peak value: 522 bp. The peak at 127 bp is adapter-
dimer. The electrophoretic run indicates that there is mostly adapter-dimer. 
 
Sample 12 
 
Figure 17. Sample 12 electropherogram. Peak value: 218 bp. The amplicon at 218 bp is 
visible in the electrophoretic run. 
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Sample 12 diluted 
 
Figure 18. Sample 12 diluted electropherogram. Peak value: 425 bp. The peak at 129 bp is 
adapter-dimer. The higher marker had to be set manually. The adapter-dimer is primarily 
visible in the electrophoretic run. 
 
Sample 13 
 
Figure 19. Sample 13 electropherogram. Peak value: 194 bp. The peak at 156 bp is adapter-
dimer. The amplicon is visible as the darker band in the electrophoretic run. 
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Sample 13 diluted 
 
Figure 20. Sample 13 diluted electropherogram. Peak value: 227 bp. The peak at 124 bp is 
adapter-dimer. Both lower and higher markers had to be set manually. The electrophoretic run 
indicates that there is a single product, but it is too large to be an acceptable amplicon size. 
 
Sample 14 
 
Figure 21. Sample 14 electropherogram. Peak value: 309 bp. The peak at 132 bp is adapter-
dimer. 
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Sample 14 diluted 
 
Figure 22. Sample 14 diluted electropherogram. Peak value: 303 bp. The peak at 128 bp is 
adapter-dimer. No clear bands are visible on the electrophoretic run. 
 
Sample 15 
 
Figure 23. Sample 15 electropherogram. Peak value: 460 bp. The peak at 145 bp is adapter-
dimer. The dimer is visible on the electrophoretic run. 
 
 
 
 
 
 
59 
 
Sample 15 diluted 
 
Figure 24. Sample 15 diluted electropherogram. Peak value: 210 bp. The peak at 130 bp is 
adapter-dimer. Only the dimer is visible on the electrophoretic run. 
 
Sample 16 
 
Figure 25. Sample 16 electropherogram. Control ECD. Peak value: 211 bp. The peak at 193 
bp is not adapter-dimer, but a product. The amplicon product is visible on the electrophoretic 
run. 
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Appendix 10. Concentrations of Samples Measured with 2100 Bioanalyzer 
 
Tables 1 and 2 show the concentrations of the samples as measured with Bioanalyzer and 
also the values chosen for subsequent use in the study because of their reliability. 
 
Table 1. Measured sample concentrations with Bioanalyzer. All of 
the sample concentrations measured with Bioanalyzer. Additional 
measurement results are indicated directly after the initial 
measurement values. Key: “d” sample was diluted for measurement, ҂ 
over the range. 
Sample # Concentrations with possible 
reruns (ng/μl) 
  
1 6.73 - - 
2 8.51 2.13 2.4 d 
3 16.89 ҂ 0.19 d 1.27 
4 3.26 - - 
5 0.41 101.26 ҂ - 
6 3.37 - - 
7 3.58 - - 
8 2.06 - - 
9 4.42 - - 
10 4.91 - - 
11 3.36 - - 
12 26.89 ҂ 4.2 d - 
13 14.64 ҂ 140.3 d  ҂ - 
14 15.65 ҂ 4.6 d - 
15 46.49 ҂ 1.1 d - 
16 7.77 - - 
 
Table 2. Usable final concentration values. The concentrations and 
molarities of samples which had consistent results, measured with 
Bioanalyzer. 
Sample # Concentration 
(ng/μl) 
Molarity (region 
175-625 bp) (nmol/l) 
1 6.73 38.9 
4 3.26 15.8 
6 3.37 19.8 
9 4.42 23.0 
10 4.91 26.1 
11 3.36 16.5 
13 14.64 66.0 
14 4.6 26.1 
16 7.77 49.5 
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Appendix 11. Validation of Amplicon Size with LabChip GXI 
 
LabChip GXI was used to revalidate the amplicon size of several samples. Figures 1-7 show 
the electropherograms of samples 2, 3, 5, 7, 8, 12 and 15. 
 
Sample 2 
 
Figure 1. Sample 2 electropherogram. Peak value: 281 bp. The peak at 133 bp is adapter-
dimer. 
 
Sample 3 
Figure 2. Sample 3 electropherogram. Peak value: 270 bp. The peak at 135 bp is adapter-
dimer. 
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Sample 5 
Figure 3. Sample 5 electropherogram. Peak value: 315 bp. The peak at 137 bp is adapter-
dimer. 
 
Sample 7 
Figure 4. Sample 7 electropherogram. Peak value: 393 bp. The peak at 135 bp is adapter-
dimer. 
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Sample 8 
Figure 5. Sample 8 electropherogram. Peak value: 274 bp. The peak at 136 bp is adapter-
dimer. 
 
Sample 12 
Figure 6. Sample 12 electropherogram. Peak value: 284 bp. The peak at 137 bp is adapter-
dimer. 
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Sample 15 
Figure 7. Sample 15 electropherogram. Peak value: 285 bp. The peak at 137 bp is adapter-
dimer. 
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Appendix 12. Concentrations of Samples Measured with LabChip 
  
Table 1. Concentrations and molarities of samples. Measured concentrations and 
molarities with LabChip.  
Sample # Concentration (ng/μl) Molarity (region 175-625 
bp) (nmol/l) 
2 1.746 9.049 
3 1.223 6.352 
5 1.472 7.607 
7 1.933 9.737 
8 1.737 9.071 
12 3.499 19.074 
15 1.443 7.842 
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Appendix 13. Sequencing Run Data 
 
Run data from MiSeq is shown in Table 1. and Figures 1-2 below. 
 
Table 1. Reads Mapped to Index ID. The table shows the total number of reads, the 
percentage of aligned reads and shows what percentages of reads have aligned to which 
samples (sample ID). 
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Figure 1. Reads Mapped to Index ID. The graph shows the distribution of the identified 
reads among the different samples sequenced. 
 
 
 
Figure 2. QScore Distribution. The plot shows the distribution of the quality score of the 
bases. 74.0% of all of the bases (green) have a quality score of over Q30. Bases with a quality 
score of less than Q30 are in blue. 26.0% of the bases have a quality score ≤ Q30. 
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Calculating sequencing coverage 
 
Coverage was calculated with the following equation: 
 
Coverage = N x L/G  
N = number of reads identified for samples 
L = average read length 
G = length of targeted region 
 
N = 15 305 716 reads  
L = 100 bp 
G = 94 607 bp x 9 samples = 851 463 bp 
 
C = 
                   
          
 = 1 797 
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Appendix 14. Sequencing and qPCR Results 
 
Sequencing 
Figure 1. shows the detected SNVs within the selected cell lines from DNA Pool 1.  
 
Figure 1. Sequencing call map. All the sequenced samples with detected SNVs are shown 
according to cell line. Only four SNVs were detected. The % of SNV = number of reads with 
SNV/total number of reads at target region. To make comparison of the fractions of DNA 
easier, samples are in order of increasing amounts of LNCaP DNA and decreasing amounts of 
MDA-MB-415 DNA.  
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Figure 2. Example of viewing with IGV. A screenshot of IGV with sample 13 being 
analyzed. There are two tracks being viewed. The top track is sample 13 and the lower track is 
sample 16 (Agilent DNA control). Both tracks have numerous reads, but only sample 13 has 
an A>G substitution at a particular coordinate, seen in the vertical path of brackets in the 
center of the screen. Directly below the last track, the reference genome can be seen. 
 
Quantitative Real-Time PCR 
The call map for qPCR genotyped samples is seen in Figure 3. 
 
 
Figure 3. qPCR call map. Shown are all the samples that were genotyped by qPCR. All 
samples are shown as triplicates. To make comparison of the DNA fractions easier, samples 
are in order of increasing amounts of LNCaP DNA and decreasing amounts of MDA-MB-
415 DNA. Some No Call results changed to SNV, XX, or YY when the confidence 
threshold was decreased from 65 to 50.  
 
